Systematic review of randomized controlled trials of misoprostol to prevent postpartum hemorrhage

被引:53
作者
Villar, J
Gülmezoglu, AM
Hofmeyr, GJ
Forna, F
机构
[1] WHO, Dept Reprod Hlth & Res, UNDP UNFPA WHO World Bank, Special Programme Res Dev & Res Training Human, CH-1211 Geneva, Switzerland
[2] Univ Witwatersrand, Effect Care Res Unit, ZA-2193 Johannesburg, South Africa
[3] Emory Univ, Sch Med, Dept Obstet & Gynecol, Atlanta, GA 30322 USA
关键词
D O I
10.1016/S0029-7844(02)02371-2
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
OBJECTIVE: To assess the effects of prophylactic misoprostol use in the third stage of labor compared with injectable uterotonics or placebo or no treatment. DATA SOURCES: The Cochrane Pregnancy and Childbirth Group trials register; the Cochrane Library, including databases such as the database of systematic reviews and the Cochrane Controlled Trials Register; and MEDLINE were searched. Researchers in the field were also contacted. The date of the latest search was March 1, 2002. METHODS OF STUDY SELECTION: Randomized trials comparing misoprostol with injectable oxytocin or oxytocinergot preparations to prevent postpartum hemorrhage or placebo/no treatment as active management of the third stage of labor were eligible for inclusion. Eligibility and trial quality were assessed following selected criteria. Data were extracted and analyzed using RevMan software. TABULATION, INTEGRATION, AND RESULTS: Sixteen randomized trials with a total of 28,138 women were considered. Data were available for 27,498 women. Oral misoprostol (600 mug) is less effective than injectable uterotonics in reducing blood loss at least 1000 mL (relative risk [RR] 1.36, 95% confidence interval [CI] 1.17, 1.58) and increases the use of additional uterotonics. Shivering and pyrexia (temperature greater than 38C) are the main side effects of misoprostol and are dose related. Compared with injectable uterotonics, the RR of "any shivering" with misoprostol (600 mug) is 3.27 (95% CI 3.01, 3.56) and pyrexia is 6.96 (95% Cl 5.65,8.57).The RR of blood loss of 500 mL or more is 1.11 (95% CI 0.87,1.43) and the RR of use of additional uterotonics is 1.80 (1.13, 2.85) in the three trials (1441 women) comparing rectal misoprostol (400 mug) with injectable uterotonics. CONCLUSION: Injectable oxytocin or oxytocin-ergot preparations are more effective than misoprostol as part of the active management of the third stage of labor. (Obstet Gynecol 2002;100:1301-12. (C) 2002 by The American College of Obstetricians and Gynecologists.)
引用
收藏
页码:1301 / 1312
页数:12
相关论文
共 47 条
[1]  
ABDELALEEM H, IN PRESS EUR J OBSTE
[2]   A randomized, controlled trial comparing effect of oral misoprostol and intravenous syntocinon on intra-operative blood loss during cesarean section [J].
Acharya, G ;
Al-Sammarai, MT ;
Patel, N ;
Al-Habib, A ;
Kiserud, T .
ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA, 2001, 80 (03) :245-250
[3]  
ALFIREVIC Z, 2000, COCHRANE DB SYST REV, V2, pC1338
[4]   Misoprostol compared with methylergometrine for the prevention of postpartum haemorrhage: a double-blind randomised trial [J].
Amant, F ;
Spitz, B ;
Timmerman, D ;
Corremans, A ;
Van Assche, FA .
BRITISH JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 1999, 106 (10) :1066-1070
[5]  
[Anonymous], IARC SCI PUBLICATION
[6]  
AUBENY E, 1991, CR ACAD SCI III-VIE, V312, P539
[7]   Rectal misoprostol in the prevention of postpartum hemorrhage: A placebo-controlled trial [J].
Bamigboye, AA ;
Hofmeyr, GJ ;
Merrell, DA .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1998, 179 (04) :1043-1046
[8]   Randomized comparison of rectal misoprostol with Syntometrine for management of third stage of labor [J].
Bamigboye, AA ;
Merrell, DA ;
Hofmeyr, GJ ;
Mitchell, R .
ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA, 1998, 77 (02) :178-181
[9]   Misoprostol for prevention of postpartum hemorrhage [J].
Bugalho, A ;
Daniel, A ;
Faúndes, A ;
Cunha, M .
INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS, 2001, 73 (01) :1-6
[10]   WHO systematic review of randomised controlled trials of routine antenatal care [J].
Carroli, G ;
Villar, J ;
Piaggio, G ;
Khan-Neelofur, D ;
Gülmezoglu, M ;
Mugford, M ;
Lumbiganon, P ;
Farnot, U ;
Bersgjo, P .
LANCET, 2001, 357 (9268) :1565-1570